Tag Archives: KCAT19

Obe-cel’s BLA Submission on Track for YE 2023; New Obe-cel Ph1 Trial to Start for SLE; Two Assets Added to the Pipeline; Autolus’s Q2 2023 Earnings Call Summary

On Thursday, August 3, Autolus held its Q2 2023 earnings call (press release / presentation) highlighting that obe-cel’s (CD19 CAR-T) BLA submission in r/r ALL is still expected by YE 2023. Of note, the company plans to start a new obe-cel trial in SLE in 2024 and added two new assets to its pipeline, including an allogeneic version of obe-cel. Below, Celltelligence provides insights on obe-cel’s pathway towards commercialization, while discussing its entry into the autoimmune space.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.